CJC-1295 + Ipamorelin

GH Axis / Body composition

GH-axis support; adaptation possible through training/body composition

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide combination
Primary mechanism: GHRH analog + ghrelin receptor agonism
Primary market use: Hormone optimization

Pharmacology

Molecular weight (Da): Blend / variable
Oral bioavailability: N/A
Half-life: CJC-DAC ~6-8 d; Ipam ~2 h
Route tags: Route-dependent / verify
Evidence level: Research
Clinical status: Compounded/research
Value-for-money score: 6 / 10

Reported protocol signal

Treatment length: 30 days Wait 2-3 hours after eating, and don’t eat for another 30 minutes after injection CJC-1295 DAC SQ: • 100 mcg twice a week (Dr. Seeds) CJC-1295 no DAC SQ: • 200 mcg nightly (5 nights on, 2 nights off) (Tailor Made Compounding Catalog) CJC-1295 no DAC is often stacked with Ipamorelin: SQ: • 200mcg/200mcg nightly (5 nights on, 2 nights off) (Tailor Made Compounding Catalog) Dr. Seeds claims that 100mcg/100mcg is more cost-effective and higher dose is only marginally better.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Core pharmacology is transient; downstream adaptations may persist

Sources

https://pubmed.ncbi.nlm.nih.gov/